發(fā)布時間：2018-11-26 09:04

【摘要】：目的:通過收集新疆醫(yī)科大學附屬腫瘤醫(yī)院治療的31例上皮樣肉瘤的臨床資料,分析上皮樣肉瘤(ES)的臨床特點、診療與預后的影響因素,為臨床的診療提供依據(jù)。方法:對我院2010年1月至2015年12月間收治并獲得隨訪31例上皮樣肉瘤臨床資料進行回顧性分析和生存分析,總結(jié)其臨床特點,術(shù)前診斷,及術(shù)后復發(fā)的相關(guān)數(shù)據(jù),以性別、年齡、腫瘤類型、腫瘤大小、有無放化療、INI1表達情況為因素,進行復發(fā)因素的相關(guān)性分析。結(jié)果:本組6例患者死亡,5年總生存率78.8%。31例均獲隨訪,隨訪時間為3-56個月,中位時間為27個月。5年復發(fā)率為70.9%,在單因素分析中,影響5年復發(fā)率的因素為腫瘤的類型及腫瘤大小,其中腫瘤5cm與≤5cm相比,腫瘤近端型與遠端型相比,前者的5年復發(fā)率均高于后者(p0.05)。全組中CD34陽性表達占90.3%,INI1表達缺失占83.9%。對于腫瘤與周圍血管神經(jīng)界限不清的患者,給予術(shù)前放療后可手術(shù)治療,避免截肢。結(jié)論:上皮樣肉瘤術(shù)前需要臨床、影像學、病理學相結(jié)合,明確診斷及鑒別診斷,廣泛切除仍是治療的主要方式。INI1的表達缺失可以幫助ES的診斷及鑒別診斷,但不能提示預后,而腫瘤大小及腫瘤類型與預后有關(guān)。術(shù)前適行調(diào)強放療可以縮小ES腫瘤大小,在局部晚期的患者中,可以避免截肢帶來的不便,提高患者收益率。
[Abstract]:Objective: to collect the clinical data of 31 cases of epithelioid sarcoma treated in Cancer Hospital affiliated to Xinjiang Medical University, analyze the clinical characteristics, diagnosis, treatment and prognostic factors of Epidermoid sarcoma (ES), and provide the basis for clinical diagnosis and treatment. Methods: the clinical data of 31 cases of epithelioid sarcoma from January 2010 to December 2015 were retrospectively analyzed and analyzed. The clinical features, preoperative diagnosis and related data of recurrence were summarized. Age, tumor type, tumor size, radiotherapy and chemotherapy, INI1 expression were used as factors. Results: the 5-year overall survival rate of 78.8.31 cases was followed up for 3-56 months and the median time was 27 months. The 5-year recurrence rate was 70.9%. The factors influencing 5-year recurrence rate were tumor type and tumor size. The 5-year recurrence rate of tumor 5cm was higher than that of distal type compared with 鈮，

本文編號：2358077